Cargando…

Natural Compounds for Counteracting Nonalcoholic Fatty Liver Disease (NAFLD): Advantages and Limitations of the Suggested Candidates

The booming prevalence of nonalcoholic fatty liver disease (NAFLD) in adults and children will threaten the health system in the upcoming years. The “multiple hit” hypothesis is the currently accepted explanation of the complex etiology and pathophysiology of the disease. Some of the critical pathol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Salvoza, Noel, Giraudi, Pablo J., Tiribelli, Claudio, Rosso, Natalia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911502/ https://www.ncbi.nlm.nih.gov/pubmed/35269912 http://dx.doi.org/10.3390/ijms23052764

Ejemplares similares

The Beneficial Effects of Triterpenic Acid and Acteoside in an In Vitro Model of Nonalcoholic Steatohepatitis (NASH)
por: Salvoza, Noel, et al.
Publicado: (2022)

Diagnostic management of nonalcoholic fatty liver disease: a transformational period in the development of diagnostic and predictive tools—a narrative review
por: Rosso, Natalia, et al.
Publicado: (2021)

Ficolin-2 Plasma Level Assesses Liver Fibrosis in Non-Alcoholic Fatty Liver Disease
por: Giraudi, Pablo J., et al.
Publicado: (2022)

Silybin Modulates Collagen Turnover in an In Vitro Model of NASH
por: Anfuso, Beatrice, et al.
Publicado: (2019)

Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis
por: Chackelevicius, Carla Melisa, et al.
Publicado: (2016)

The OMICs Window into Nonalcoholic Fatty Liver Disease (NAFLD)
por: Carulli, Lucia, et al.
Publicado: (2019)

Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
por: Drescher, Hannah K., et al.
Publicado: (2019)

Genetic and Epigenetic Regulation in Nonalcoholic Fatty Liver Disease (NAFLD)
por: Del Campo, José A, et al.
Publicado: (2018)

Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD)
por: Zarghamravanbakhsh, Paria, et al.
Publicado: (2021)

Nonalcoholic Fatty Liver Disease (NAFLD): Pathogenesis and Noninvasive Diagnosis
por: Dorairaj, Vicneswarry, et al.
Publicado: (2021)

Nutritional Management of Insulin Resistance in Nonalcoholic Fatty Liver Disease (NAFLD)
por: Conlon, Beth A., et al.
Publicado: (2013)

Nonalcoholic Fatty Liver Disease (NAFLD) Name Change: Requiem or Reveille?
por: Singh, Shivaram P., et al.
Publicado: (2021)

Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?
por: Di Ciaula, Agostino, et al.
Publicado: (2021)

Mouse models of nonalcoholic fatty liver disease (NAFLD): pathomechanisms and pharmacotherapies
por: Fang, Tingyu, et al.
Publicado: (2022)

Clustering NAFLD: phenotypes of nonalcoholic fatty liver disease and their differing trajectories
por: Kantartzis, Konstantinos, et al.
Publicado: (2023)

The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
por: Younossi, Zobair M., et al.
Publicado: (2023)

Role of Oxidative Stress in Hepatic and Extrahepatic Dysfunctions during Nonalcoholic Fatty Liver Disease (NAFLD)
por: Gonzalez, Andrea, et al.
Publicado: (2020)

Effects of Natural Products on Fructose-Induced Nonalcoholic Fatty Liver Disease (NAFLD)
por: Chen, Qian, et al.
Publicado: (2017)

Sex Dimorphism of Nonalcoholic Fatty Liver Disease (NAFLD) in Pparg-Null Mice
por: Schiffrin, Mariano, et al.
Publicado: (2021)

Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans
por: Pafili, Kalliopi, et al.
Publicado: (2020)

Noninvasive assessment of fibrosis among patients with nonalcoholic fatty liver disease [NAFLD]
por: Bernstein, David, et al.
Publicado: (2022)

Altered serum acylcarnitine profile is associated with the status of nonalcoholic fatty liver disease (NAFLD) and NAFLD-related hepatocellular carcinoma
por: Enooku, Kenichiro, et al.
Publicado: (2019)

The pediatric NAFLD fibrosis index: a predictor of liver fibrosis in children with non-alcoholic fatty liver disease
por: Nobili, Valerio, et al.
Publicado: (2009)

Nonalcoholic Fatty Liver Disease and Altered Neuropsychological Functions in Patients with Subcortical Vascular Dementia
por: Moretti, Rita, et al.
Publicado: (2022)

Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD)
por: Polyzos, Stergios A., et al.
Publicado: (2020)

Innovative Molecular Target and Therapeutic Approaches in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) 2.0
por: Vairetti, Mariapia, et al.
Publicado: (2022)

Sugar-Sweetened Beverages and Artificially Sweetened Beverages Consumption and the Risk of Nonalcoholic Fatty Liver (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
por: Tseng, Tung-Sung, et al.
Publicado: (2023)

Prevalence of Prediabetes and Diabetes and Metabolic Profile of Patients With Nonalcoholic Fatty Liver Disease (NAFLD)
por: Ortiz-Lopez, Carolina, et al.
Publicado: (2012)

Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD)
por: Raszeja-Wyszomirska, Joanna, et al.
Publicado: (2010)

Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD)
por: Golabi, Pegah, et al.
Publicado: (2018)

Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus
por: Portillo-Sanchez, Paola, et al.
Publicado: (2016)

Nonalcoholic Fatty Liver Disease (NAFLD) and Hepatic Cytochrome P450 (CYP) Enzymes
por: Jamwal, Rohitash, et al.
Publicado: (2020)

PIN1, a perspective on genetic biomarker for nonalcoholic fatty liver disease (NAFLD)
por: Wang, Jing-Zhang, et al.
Publicado: (2019)

Endothelial Cell Dysfunction and Nonalcoholic Fatty Liver Disease (NAFLD): A Concise Review
por: Nasiri-Ansari, Narjes, et al.
Publicado: (2022)

Genetic Polymorphisms and Diversity in Nonalcoholic Fatty Liver Disease (NAFLD): A Mini Review
por: Sulaiman, Siti Aishah, et al.
Publicado: (2022)

Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score
por: Tapper, Elliot B., et al.
Publicado: (2016)

Required warfarin dose and time in therapeutic range in patients with diagnosed Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)
por: Wen, Xuerong, et al.
Publicado: (2021)

Validation of nonalcoholic fatty liver disease (NAFLD) related steatosis indices in metabolic associated fatty liver disease (MAFLD) and comparison of the diagnostic accuracy between NAFLD and MAFLD
por: Chen, Jie, et al.
Publicado: (2023)

Association between PPARGC1A polymorphisms and the occurrence of nonalcoholic fatty liver disease (NAFLD)
por: Yoneda, Masato, et al.
Publicado: (2008)

Obesity, Visceral Fat, and NAFLD: Querying the Role of Adipokines in the Progression of Nonalcoholic Fatty Liver Disease
por: Mirza, M. S.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_7p80no9q4he8ij40lqumv6d8r2